PL3046412T3 - Przekształcone histydyną łańcuchy lekkie przeciwciał i genetycznie zmodyfikowane zwierzęta inne niż człowiek do ich wytwarzania - Google Patents

Przekształcone histydyną łańcuchy lekkie przeciwciał i genetycznie zmodyfikowane zwierzęta inne niż człowiek do ich wytwarzania

Info

Publication number
PL3046412T3
PL3046412T3 PL14781761T PL14781761T PL3046412T3 PL 3046412 T3 PL3046412 T3 PL 3046412T3 PL 14781761 T PL14781761 T PL 14781761T PL 14781761 T PL14781761 T PL 14781761T PL 3046412 T3 PL3046412 T3 PL 3046412T3
Authority
PL
Poland
Prior art keywords
generating
light chain
same
genetically modified
chain antibodies
Prior art date
Application number
PL14781761T
Other languages
English (en)
Inventor
John Mcwhirter
Lynn Macdonald
Andrew J Murphy
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/030,424 external-priority patent/US20140013456A1/en
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of PL3046412T3 publication Critical patent/PL3046412T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027New or modified breeds of vertebrates
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027New or modified breeds of vertebrates
    • A01K67/0275Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278Knock-in vertebrates, e.g. humanised vertebrates
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00Modified animals
    • A01K2207/15Humanized animals
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00Genetically modified animals
    • A01K2217/07Animals genetically altered by homologous recombination
    • A01K2217/072Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00Genetically modified animals
    • A01K2217/15Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00Animals characterised by species
    • A01K2227/10Mammal
    • A01K2227/105Murine
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00Animals characterised by purpose
    • A01K2267/01Animal expressing industrially exogenous proteins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51Complete heavy chain or Fd fragment, i.e. VH + CH1
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515Complete light chain, i.e. VL + CL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Environmental Sciences (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
PL14781761T 2013-09-18 2014-09-18 Przekształcone histydyną łańcuchy lekkie przeciwciał i genetycznie zmodyfikowane zwierzęta inne niż człowiek do ich wytwarzania PL3046412T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14/030,424 US20140013456A1 (en) 2012-03-16 2013-09-18 Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
EP14781761.3A EP3046412B1 (en) 2013-09-18 2014-09-18 Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same
PCT/US2014/056285 WO2015042250A1 (en) 2013-09-18 2014-09-18 Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same

Publications (1)

Publication Number Publication Date
PL3046412T3 true PL3046412T3 (pl) 2019-11-29

Family

ID=51663490

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14781761T PL3046412T3 (pl) 2013-09-18 2014-09-18 Przekształcone histydyną łańcuchy lekkie przeciwciał i genetycznie zmodyfikowane zwierzęta inne niż człowiek do ich wytwarzania

Country Status (25)

Country Link
EP (2) EP3046412B1 (pl)
JP (3) JP6621750B2 (pl)
KR (2) KR102150414B1 (pl)
CN (2) CN111019953A (pl)
AU (2) AU2014323527B2 (pl)
BR (1) BR112016005912A2 (pl)
CA (1) CA2922892C (pl)
CY (1) CY1121798T1 (pl)
DK (1) DK3046412T3 (pl)
ES (2) ES2738679T3 (pl)
HK (1) HK1225913A1 (pl)
HR (1) HRP20191233T1 (pl)
HU (1) HUE044747T2 (pl)
IL (2) IL244226B (pl)
LT (1) LT3046412T (pl)
MX (1) MX362904B (pl)
MY (1) MY191512A (pl)
PL (1) PL3046412T3 (pl)
PT (1) PT3046412T (pl)
RS (1) RS59003B1 (pl)
RU (2) RU2019121863A (pl)
SG (2) SG11201601272YA (pl)
SI (1) SI3046412T1 (pl)
TR (1) TR201909967T4 (pl)
WO (1) WO2015042250A1 (pl)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140093496A1 (en) 2011-02-25 2014-04-03 Chugai Seiyaku Kabushiki Kaisha Fc-gamma-RIIb-SPECIFIC Fc ANTIBODY
JP6322411B2 (ja) 2011-09-30 2018-05-09 中外製薬株式会社 複数の生理活性を有する抗原の消失を促進する抗原結合分子
US20150056182A1 (en) 2011-11-30 2015-02-26 Chugai Seiyaku Kabushiki Kaisha Drug containing carrier into cell for forming immune complex
TWI717591B (zh) 2012-08-24 2021-02-01 日商中外製藥股份有限公司 FcγRIIb特異性Fc區域變異體
ES2876009T3 (es) 2012-12-27 2021-11-11 Chugai Pharmaceutical Co Ltd Polipéptido heterodimerizado
CA2908350C (en) 2013-04-02 2023-08-08 Futa Mimoto Fc region variant
MA41294A (fr) 2014-12-19 2017-11-08 Chugai Pharmaceutical Co Ltd Anticorps anti-myostatine, polypeptides contenant des variants de régions fc, et procédés d'utilisation
WO2016125495A1 (en) 2015-02-05 2016-08-11 Chugai Seiyaku Kabushiki Kaisha Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof
US11359009B2 (en) 2015-12-25 2022-06-14 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
RU2766112C2 (ru) 2016-08-05 2022-02-08 Чугаи Сейяку Кабусики Кайся Композиция для профилактики или лечения связанных с il-8 заболеваний
US20220090125A1 (en) * 2018-12-21 2022-03-24 Compass Therapeutics Llc Transgenic mouse expressing common human light chain
EP4075965A1 (en) * 2019-12-18 2022-10-26 Bristol-Myers Squibb Company Bcr transgenic mice with a common leader sequence
AU2021342159A1 (en) 2020-09-11 2023-03-02 Regeneron Pharmaceuticals, Inc. Identification and production of antigen-specific antibodies
IL303626A (en) 2020-12-16 2023-08-01 Regeneron Pharma Mice expressing human FC alpha receptors
CN114568343B (zh) * 2022-03-11 2023-04-07 成都合拓创展生物科技有限公司 制备眼病模型的头具及其应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6774279B2 (en) 1997-05-30 2004-08-10 Carnegie Institution Of Washington Use of FLP recombinase in mice
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7294754B2 (en) 2004-10-19 2007-11-13 Regeneron Pharmaceuticals, Inc. Method for generating an animal homozygous for a genetic modification
WO2007117410A2 (en) * 2006-03-31 2007-10-18 Medarex, Inc. Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
SI2041177T1 (sl) 2006-06-02 2012-03-30 Regeneron Pharma Visoko afinitetna protitelesa za humani IL receptor
CN103251948A (zh) * 2008-04-11 2013-08-21 中外制药株式会社 与多个分子的抗原反复结合的抗原结合分子
AU2009313389A1 (en) * 2008-11-06 2010-05-14 Alexion Pharmaceuticals, Inc. Engineered antibodies with reduced immunogenicity and methods of making
TWI507525B (zh) 2009-06-26 2015-11-11 Regeneron Pharma 具天然免疫球蛋白形式之易分離的雙專一性抗體
WO2011008096A1 (en) 2009-07-16 2011-01-20 Wageningen Universiteit Regulation of zinc deficiency and tolerance in plants
RU2425880C2 (ru) * 2009-07-30 2011-08-10 Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН Способ получения трансгенных мышей
CN102803491A (zh) * 2010-01-21 2012-11-28 奥克西雷恩英国有限公司 用于在酵母细胞表面上展示多肽的方法和组合物
US20130185821A1 (en) 2010-02-08 2013-07-18 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
RS59001B1 (sr) 2010-02-08 2019-08-30 Regeneron Pharma Miš sa zajedničkim lakim lancem
US20120021409A1 (en) * 2010-02-08 2012-01-26 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
SG183867A1 (en) * 2010-03-11 2012-10-30 Rinat Neuroscience Corp ANTIBODIES WITH pH DEPENDENT ANTIGEN BINDING
ES2576928T3 (es) * 2010-06-22 2016-07-12 Regeneron Pharmaceuticals, Inc. Ratones que expresan una cadena ligera con las regiones variable lambda humana y constante de ratón
AU2011331129B2 (en) * 2010-11-19 2016-10-06 Morphosys Ag A collection and methods for its use
KR102528622B1 (ko) * 2011-09-30 2023-05-04 추가이 세이야쿠 가부시키가이샤 이온 농도 의존성 결합 분자 라이브러리
US20140013456A1 (en) * 2012-03-16 2014-01-09 Regeneron Pharmaceuticals, Inc. Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
KR20160025033A (ko) * 2013-02-20 2016-03-07 리제너론 파마슈티칼스 인코포레이티드 변형된 면역글로불린 중쇄 서열을 갖는 비인간 동물

Also Published As

Publication number Publication date
HK1225913A1 (zh) 2017-09-22
MY191512A (en) 2022-06-28
KR102150414B1 (ko) 2020-09-02
ES2738679T3 (es) 2020-01-24
HUE044747T2 (hu) 2019-11-28
ES2962489T3 (es) 2024-03-19
CN105722387A (zh) 2016-06-29
MX362904B (es) 2019-02-25
AU2014323527A1 (en) 2016-04-07
JP2016533768A (ja) 2016-11-04
WO2015042250A9 (en) 2016-04-28
SG11201601272YA (en) 2016-03-30
EP3549437A1 (en) 2019-10-09
IL244226B (en) 2019-02-28
KR20160049018A (ko) 2016-05-04
CY1121798T1 (el) 2020-07-31
RU2019121863A (ru) 2019-08-29
CN111019953A (zh) 2020-04-17
PT3046412T (pt) 2019-07-16
BR112016005912A2 (pt) 2017-09-26
EP3549437B1 (en) 2023-10-25
RU2016114306A3 (pl) 2018-04-26
AU2014323527B2 (en) 2020-10-15
JP6621750B2 (ja) 2019-12-18
WO2015042250A4 (en) 2015-05-28
IL264358A (en) 2019-02-28
IL244226A0 (en) 2016-04-21
EP3046412B1 (en) 2019-04-10
MX2016003638A (es) 2016-07-21
RU2016114306A (ru) 2017-10-23
HRP20191233T1 (hr) 2019-10-18
EP3046412A1 (en) 2016-07-27
CA2922892C (en) 2022-06-14
RU2694728C2 (ru) 2019-07-16
EP3549437C0 (en) 2023-10-25
AU2021200228A1 (en) 2021-03-18
SI3046412T1 (sl) 2019-08-30
DK3046412T3 (da) 2019-07-15
JP2020078350A (ja) 2020-05-28
CA2922892A1 (en) 2015-03-26
WO2015042250A1 (en) 2015-03-26
RS59003B1 (sr) 2019-08-30
KR20200103882A (ko) 2020-09-02
JP2019068850A (ja) 2019-05-09
CN105722387B (zh) 2020-01-17
SG10201810825YA (en) 2019-01-30
TR201909967T4 (tr) 2019-07-22
LT3046412T (lt) 2019-07-25

Similar Documents

Publication Publication Date Title
IL282452B (en) Histidine-engineered light chain antibodies, and non-human animals genetically modified for their preparation
IL264358A (en) Histidine engineered light chain antibodies and non-human animals genetically engineered to produce them
HK1258227A1 (zh) 具有修飾的免疫球蛋白重鏈序列的非人類動物